Flavonoids for treating venous leg ulcers

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2007, Pages

  Scallon, Christopher ^a   Bell Syer, S E M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALVENOR; ANTHOCYANIN; ARDIUM; ARVENUM 500; BENZOFLAVONE DERIVATIVE; BIFLAVONOID; CAPIVEN; CATECHIN; CHALCONE DERIVATIVE; DAFLON; DETRALEX; DIOSMIN; ELATEC; FLAVAN DERIVATIVE; FLAVONE DERIVATIVE; FLAVONOID; FLEBOTROPIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HESPERIDIN; MESOGLYCAN; PLACEBO; PROANTHOCYANIDIN; PROCYANIDOL OLIGOMER; SULODEXIDE; VARITON; VENITOL;

CLINICAL TRIAL; COMPRESSION; CONTROLLED CLINICAL TRIAL; DRUG ACTIVITY; HUMAN; INTERMETHOD COMPARISON; LEG ULCER; OUTCOME ASSESSMENT; PATHOGENESIS; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; ULCER HEALING;

EID: 44949194781     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006477     Document Type: Review

References (49)

1. Altman 1999 Altman, D.G, Bland. J.M. Treatment allocation in controlled trials: why randomise?. British Medical Journal 1999;318:1209.
2. Anonymous (1) 2004 Anonymous. The role of Daflon 500 mg in the treatment of symptomatic patients with varicose veins. Phlebolymphology 2004;47:320-3.
3. Anonymous (2) 2004 Anonymous. Diosmin. Alternative Medicine Review 2004;9(3):308-11.
4. Araujo 2003 Araujo T, Valencia I, Federman DG, Kirsner RS. Managing the patient with venous ulcers. Annals of Internal Medicine 2003;138(4):326-34.
5. Bergan 2005 Bergan JJ. Chronic venous insufficiency and the therapeutic effects of Daflon 500 mg. Angiology 2005;56:21-4.
6. Cochrane 2005 Higgins JTP, Green S, editors. Cochrane handbook for systematic reviews of interventions 4.2.5 [updated May 2005]. www.cochrane.org/resources/handbook/hbook.htm.
7. Coleridge 2000a Coleridge-Smith PD.Micronized purified flavonoid fraction and the treatment of chronic venous insufficiency: microcirculatory mechanisms. Microcirculation 2000;7(6):35-40.
8. Coleridge 2003 Coleridge-Smith PD. Fromskin disorders to venous leg ulcers: pathophysiology and efficacy of Daflon 500 mg in ulcer healing. Angiology 2003;54:45-50.
9. Coleridge 2005 Coleridge-Smith PD, Lok C, Ramelet AA. Venous leg ulcer: A meta-analysis of adjunctive therapy with micronized purified flavonoid fraction. European Journal of Vascular and Endovascular Surgery 2005;30:198-208.
10. Colgan 1992 Colgan MP, Moore DJ, Shanik DG. Drug therapy for venous ulcers: new methods of treatment. Phlebology 1992;7:41-3.
11. CRD Report 1996 Undertaking systematic reviews of research on effectiveness. CRD guidelines for those carrying out or commissioning reviews 1996.
12. Cullum 2001 Cullum N, Nelson EA, Fletcher AW, Sheldon TA. Compression for venous leg ulcers. Cochrane Database of Systematic Reviews 2001, Issue 2.Art. No.: CD000265. DOI:10.1002/14651858.CD000265.
13. Dale 1995 Dale J. The aetiology of leg ulceration. In: Cullum, N editor(s). Leg ulcers: nursing management - a research-based guide. Scutari Press, 1995.
14. Egger 1998 Egger M, Davey-Smith G. Meta-analysis bias in location and selection of studies. BMJ 1998;316:61-6.
15. Glasziou 2001 Glasziou P, Irwiq L, Bain C, Colditz G. Systematic reviews in health care: a practical guide. University of Cambridge Press: Cambridge, 2001.
16. Glinski 1999 Glinski W, Chodynicka B, Roskiewicz J, Bogdanowski T, et al.The beneficial augmentative effect of micronized purified flavonoid fraction (MPFF) on the healing of leg ulcers: a multicenter controlled study. Phlebology 1999;14:151-7.
17. Guilhou 1997 Guilhou JJ, Dereure O, Marzin L, Ouvry P, Zuccarelli F, Debure C, et al.Efficacy of Daflon 500 mg in venous leg ulcer healing: a doubleblind, controlled versus placebo trial in 107 patients. Angiology 1997;48(1):77-85.
18. Hasanoglu 2001 Hasanoglu A, Ara C, Ozen S, Kali K, Senol M, Ertas E. Efficacy of micronized flavonoid fraction in healing of clean and infected wounds. International Journal of Angiology 2001;10:41-4.
19. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327:557-60.
20. Howlader 2004 Howlader M, Coleridge-Smith PD. Chronic venous disease and venous ulcer: pharmacological approach. Journal of Cardiovascular Diseases 2004;2(1):33-41.
21. Jull 2002 Jull AB, Waters J, Arroll, B. Pentoxifylline for treating venous leg ulcers. Cochrane Database of Systematic Reviews 2002, Issue 1.Art. No.: CD001733. DOI:10.1002/14651858.CD001733.pub2.
22. Juni 2001 Juni P, Altman DG, Egger M. Assessing the quality of randomised controlled trials. In: Egger M, Davey-Smith G, Altman DG editor(s). Systematic Reviews in Health Care: Meta-analysis in context. London: BMJ Publishing Group, 2001:87-108.
23. Katsenis 2005 Katsenis K. Micronized purified flavonoid fraction (MPFF): a review of its pharmacological effects, therapeutic efficacy and benefits in the management of chronic venous insufficiency. Current Vascular Pharmacology 2005;3(1):1-9.
24. Khan 2003 Khan KS, Kunz R, Kleijnen J, Antes G. Systematic reviews to support evidence-based medicine: how to review and apply findings of healthcare research. Royal Society of Medicine Press Ltd, 2003.
25. Konstantinos 2005 Konstantinos K. Micronized purified flavonoid fraction (MPFF)*: A review of its pharmacological effects, therapeutic efficacy and benefits in the management of chronic venous insufficiency. Current Vascular Pharmacology 2005;3:1-9.
26. Lyseng 2003 Lyseng-Williamson KA, Perry CM. Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids. Drugs 2003;61:71-100.
27. Mann 1981 Mann RJ. A double-blind trial of oral O. B-hydroxyethyl rutosides for stasis leg ulcers. British Journal of Clinical Practice 1981;35:79-81.
28. Margolis 1994 Margolis DJ Cohen JH. Management of chronic venous leg ulcers: a literature-guided approach. Clinics in Dermatology 1994;12(1):19-26.
29. Martinez 2005 Martinez MJ, Bonfill X, Moreno RM, Vargas E, Capella D. Phlebotonics for venous insufficiency. Cochrane Database of Systematic Reviews 2005, Issue 3.Art. No.: CD003229. DOI: 10.1002/14651858.CD003229. pub2.
30. McManus 1998 McManus RJ, Wilson S, Delaney BC, Fitzmaurice DA, Hyde CJ, Tobias RS, et al.Review of the usefulness of contacting other experts when conducting a literature search for systematic reviews. BMJ 1998;317:1562-3.
31. Moher 1995 Moher D, Jadad AR, Nichol G, Penman M, Tugwell P, Walsh S. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Controlled Clinical Trials 1995;16(1):62-73.
32. Moher 1999 Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports ofmeta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999;354(9193):1896-900.
33. Nelson 2006 Nelson EA, Cullum N, Jones J. Venous leg ulcers. Clinical Evidence 2006;15:1-3.
34. Orsted 2001 Orsted HL, Radke L, Gorst R. The impact of musculoskeletal changes on the dynamics of the calf muscle pump. Ostomy Wound Management 2001;47(10):18-24.
35. Pascarella 2005 Pascarella L, Schonbein GWS, Bergan JJ. Microcirculation and venous ulcers: A review. Annals of Vascular Surgery 2005;19(6):921-7.
36. Sannomiya 2005 Sannomiya M, Fonseca VB, da Silva MA, Rocha LR, Dos Santos LC, Hiruma-Lima CA, et. al. Flavonoids and antiulcerogenic activity from Byrsonima crassa leaves extracts. Journal of Ethnopharmacology 2005;97(1):1-6.
37. Shephard 2002 Shephard D. Daflon 500 mg in international guidelines: the reference treatment, whatever the stage of chronic venous insufficiency. Phlebolymphology 2002;38:81-4.
38. Simka 2003 Simka M Majewski E. The social and economic burden of venous leg ulcers: focus on the role of micronized purified flavonoid fraction adjuvant therapy. American Journal of Clinical Dermatology 2003;4 (8):573-81.
39. Simon 2004 Simon DA, Dix FP, McCollum CN. Management of venous leg ulcers. BMJ 2004;328:1358-62.
40. Stegmann 1986 Stegmann WAE, Deichmann B, Hubner K, Muller B. Therapeutic benefit of hydroxyethylrutosides (HR) in venous ulcer treatment. A controlled multicentre study. Phlebology 1986:617-20.
41. Struckmann 1999 Struckmann JR. Clinical efficacy of micronized purified flavonoid fraction: an overview. Journal of Vascular Research 1999;36(suppl 1): 37-41.
42. Tajana 1988 Tajana A, Boccasanta P, Micheletto G, Orio A. Results of the use of topical diosmin (venosmine) in the treatment of acute haemmorhoid pathology. Minerva Medica 1988;79(5):387-90.
43. Thompson 1994 Thompson SG. Systematic review: why sourse of heterogeneity in meta-analysis should be investigated. BMJ 1994;309:1351-5.
44. Torgerson 2003 Torgerson C. Systematic Reviews. Continuum International Publishing Group, 2003.
45. Treasure 1998 Treasure T MacRae K. Minimisation: the platinum standard for trials? - Randomisation doesn't guarantee similarity of groups; minimisation does. BMJ 1998;317:362-3.
46. Trent 2005 Trent JT, Falabella A, Eaglstein WH, Kirsner RS. Venous ulcers: Pathophysiology and treatment options. Ostomy Wound Management 2005;51(5):38-54.
47. Valencia 2001 Valencia IC, Falabella A, Kirsner RS, Eaglstein WH. Chronic venous insufficiency and venous leg ulceration. Journal of the American Academy of Dermatology 2001;44(3):401-24.
48. Wadworth 1992 Wadworth AN, Faulds D. Hydroxyethylrutosides. A review of its pharmacology and therapeutic efficacy in venous insufficiency and related disorders. Drugs 1992;44(6):1013-32.
49. Wright 1991 Wright DD, Franks PJ, Blair SD, Backhouse CM, Moffat C, McCollum CN. Oxerutins in the prevention of recurrence in chronic venous insufficiency: randomized controlled trial. British Journal of Surgery 1991;78(10):1269-70.